Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/Ledipasvir in HCV Infected Children
NCT03764345Completed
- Sponsor
- National Liver Institute
- Start
- Dec 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ledipasvir and sofosbuvir in hepatitis C (HCV), sponsored by National Liver Institute. Primary endpoint: Incidence of Adverse Events at 8 weeks. Started Dec 2018; status: completed.
02
Drugs
ledipasvirsofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03764345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764345.